



26th February 2009

Helen Chung  
Technical Adviser - Appraisals CHTE,  
National Institute for Health and Clinical Excellence,  
Level 1A,  
City Tower,  
Piccadilly Plaza,  
Manchester M1 4BD

Dear Helen,

**Lenalidomide: NICE technology appraisal**

Thank you for your request for further clarification with regard to thalidomide.

[Redacted]

[Redacted]

[Redacted]

[REDACTED]

There are no reliable data currently available from comparative Phase III clinical studies to irrevocably demonstrate the benefits of thalidomide in the treatment of relapsed refractory multiple myeloma. [REDACTED]

[REDACTED]

Please don't hesitate to contact me if you require any further information.

Yours sincerely,

[REDACTED]

Celgene Ltd  
Morgan House  
Madeira Walk  
Windsor SL4 1EP